Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 4, 2019
Reporting Period: Single event date (September 4, 2019)
Business Context: The filing discloses a Regulation FD event regarding the Company's NeuLiv® development program for the treatment of nonalcoholic steatohepatitis (NASH).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document serves solely to announce a scheduled presentation at an investment conference.
Guidance, Outlook, and Management Commentary
- Event: The Company announced it will introduce its NeuLiv® development program for the treatment of nonalcoholic steatohepatitis (NASH).
- Forum: The presentation is scheduled for the H.C. Wainwright 21st Annual Global Investment Conference in New York.
- Disclosure: A press release detailing this announcement is furnished as Exhibit 99.1.
- Legal Status: The press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the date and time of the H.C. Wainwright 21st Annual Global Investment Conference presentation.
- Review the content of the press release (Exhibit 99.1) for specific details on the NeuLiv® program status.
- Confirm the Company's status as an emerging growth company (indicated as yes in the filing).
- Check subsequent filings for any updates on the NASH program following the conference presentation.